Causal model of insight and psychopathology based on the PANSS factors: 1-year cross-sectional and longitudinal revalidation

International Clinical Psychopharmacology

Volumn 24, Issue 4, 2009, Pages 189-198

  Hwang, Samuel Suk Hyun ^a,b   Chang, Jae Seung ^c   Lee, Kyu Young ^d   Kim, Se Hyun ^b   Ahn, Yong Min ^b   Kim, Yong Sik ^a,b  

^a Interdisciplinary Program in Brain Science   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Eulji General Hospital   (South Korea)

Author keywords

Activation; Anxiety depressive factor; Causal model of insight; Longitudinal changes in psychopathology; Schizophrenia

Indexed keywords

AMISULPRIDE; NEUROLEPTIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; DEPRESSION; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MODEL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCORING SYSTEM; VALIDATION PROCESS; VALIDITY;

EID: 67651207813     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32832d6bca     Document Type: Article

References (44)

1. Ahn YM, Lee KY, Kim C, Kim J, Kang D, Jun T, et al. (2009). Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls. J Clin Psychopharmacol 29:117-123.
2. Amador XF, Strauss DH, Yale S, Gorman JM (1991). Awareness of illness in schizophrenia. Schizophr Bull 17:113-132.
3. Amador XF, Strauss DH, Yale S, Gorman JM, Endicott J (1993). The assessment of insight in psychosis. Am J Psychiatry 150:873-879.
4. Couture SM, Roberts DL, Penn DL, Cather C, Otto MW, Goff D (2006). Do baseline characteristics predict the therapeutic alliance in the treatment of schizophrenia. J Nerv Ment Dis 94:10-14.
5. Cuesta MJ, Peralta V, Zarzuela A, Zandio M (2006). Insight dimensions and cognitive function in psychosis: a longitudinal study. BMC Psychiatry 6:26.
6. David A, van Os J, Jones P, Harvey I, Foerster A, Fahy T (1995). Insight and psychotic illness. Cross-sectional and longitudinal associations. Br J Psychiatry 167:621-628.
7. Davis AS (1990). Insight and psychosis. Br J Psychiatry 156:798-808.
8. Dollfus S, Petit M (1995). Principal-component analyses of PANSS and SANS-SAPS in schizophrenia: their stability in acute phase. Eur J Psychiatry 8:97-106.
9. Drake RJ, Pickles A, Bentall RP, Kinderman P, Haddock G, Tarrierand N, Lewis SW (2004). The evolution of insight, paranoia and depression during early schizophrenia. Psychol Med 34:285-292.
10. Emsley RA, Oosthuizen PP, Joubert AF, Roberts MC, Stein DJ (1999). Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. J Clin Psychiatry 60:747-751.
11. Eskey A (1958). Insight and prognosis. J Clin Psychol 14:426-429
12. Ghaemi SN, Rosenquist KJ (2004). Is insight in mania state-dependent? A metaanalysis. J Nerv Ment Dis 192:771-775.
13. Ghaemi SN, Boiman E, Goodwin FK (2000). Insight and outcome in bipolar, unipolar, and anxiety disorders. Compr Psychiatry 41:167-171.
14. Gharabawi GM, Lasser RA, Bossie CA, Zhu Y, Amador X (2006). Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. Int Clin Psychopharmacol 21:233-240.
15. Guillem F, Pampoulova T, Stip E, Lalonde P, Todorov C (2005). The relationships between symptom dimensions and dysphoria in schizophrenia. Schizophr Res 75:83-96.
16. Hayashi N, Yamashina M, Taguchi H, Ishige N, Igarashi Y (2001). Schizophrenic outpatient perceptions of psychiatric treatment and psychotic symptomatology: an investigation using structural equation modeling. Psychiatry Clin Neurosci 55:587-593.
17. Hwang SS, Chang JS, Lee KY, Ahn YM, Kim YS (2009). The causal model of insight in schizophrenia based on the Positive and Negative Syndrome Scale factors and the structural equation modeling. J Nerv Ment Dis 197:79-84.
18. Karow A, Pajonk FG (2006). Insight and quality of life in schizophrenia: recent findings and treatment implications. Curr Opin Psychiatry 19:637-641.
19. Kemp RA, Lambert TJR (1995). Insight in schizophrenia and its relationship to psychopathology. Schizophr Res 18:21-28.
20. Kulhara K, Chandiramani K (1990). Positive and negative subtypes of schizophrenia: a follow-up study from India. Schizophr Res 9:11-18.
21. Lancon C, Auquier P, Nayt G, Reine G (2000). Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr Res 42:231-239.
22. Lancǎon C, Auquier P, Reine G, Bernard D, Addington D (2001). Relationships between depression and psychotic symptoms of schizophrenia during an acute episode and stable period. Schizophr Res 47:135-140.
23. Lincoln TM, Lüllmann E, Rief W (2007). Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophr Bull 33:1324-1342.
24. Lindenmayer JP, Brown E, Baker RW, Schuh LM, Shao L, Tohen M, et al. (2004). An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res 68:331-337.
25. Loza B, Kucharska-Pietura K, Kopacz G, Debowska G (2003). Factor Structure of Paranoid Schizophrenia: a prospective study. Psychopathology 36:132-141.
26. McEvoy JP, Freter S, Everett G, Geller J, Appelbaum P, Apperson LJ, Roth L (1989). Insight and the clinical outcome of schizophrenia patients. J Nerv Ment Dis 177:48-51.
27. Mintz AR, Dobson KS, Romney DM (2003). Insight in schizophrenia: a metaanalysis. Schizophr Res 61:75-88.
28. Mintz AR, Addington J, Addington D (2004). Insight in early psychosis: a 1-year follow-up. Schizophr Res 67:213-217.
29. Mojtabai R (1999). Duration of illness and structure of symptoms in schizophrenia. Psychol Med 29:915-924.
30. Monteiro LC, Silva VA, Louzaëæ MR (2008). Insight, cognitive dysfunction and symptomatology in schizophrenia. Eur Arch Psychiatry Clin [on-line publication].
31. Nkam I, Langlois-Thery S, Dollfus S, Petit M, (1997). Negative symptoms, depression, anxiety and alexithymia in DSM III-R schizophrenic patients. Encephale. 23:267-272.
32. Norman RM, Malla AK (1991). Dysphoric mood and symptomatology in schizophrenia. Psychol Med 21:897-903.
33. Peralta V, Cuesta MJ (2001). How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr Res 49:269-285.
34. Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF (2001). Patterns of symptoms in neuroleptic-naive patients with schizophrenia and related psychotic disorders before and after treatment. Psychiatry Res 105:97-105.
35. Pini S, Vassano GB, Dell'Osso L, Xavier FA (2001). Insight into illness in schizophrenia, schizoaffective disorder, and mood disorder with psychotic features. Am J Psychiatry 158:122-125.
36. Saeedi H, Addington J, Addington D (2007). The association of insight with psychotic symptoms, depression, and cognition in early psychosis: a 3-year follow-up. Schizophr Res 89:123-128.
37. Sax KW, Strakowski SM, Keck PE, Upadhyaya VH,West SA, McElroy SL (1996). Relationship among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. Br J Psychiatry 168:68-71.
38. Smith TE, Hull JW, Santos L (1998). The relationship between symptoms and insight in schizophrenia: a longitudinal perspective. Schizophr Res 33:63-67.
39. Storosum JG, Elferink AJ, van Zwieten BJ, van Strik R, Hoogendijk WJ, Broekmans AW (2002). Amisulpride: is there a treatment for negative symptoms in schizophrenia patients? Schizophr Bull 28:193-201.
40. Van Putten T, Crumpton E, Yale C (1976). Drug refusal in schizophrenia and the wish to be crazy. Ach Gen Psychiatry 33:1443-1446.
41. Varga M, Magnusson A, Flekkãy K, David AS, Opjordsmoen S (2007). Clinical and neuropsychological correlates of insight in schizophrenia and bipolar I disorder: does diagnosis matter? Compr Psychiatry 48:583-591.
42. Ventura J, Nuechterlein KH, Green MF, Horan WP, Subotnik KL, Mintz J (2004). The timing of negative symptom exacerbations in relationship to positive symptom exacerbations in the early course of schizophrenia. Schizophr Res 69:333-342.
43. Weiler MA, Fleisher MH, McArther-Campbell D (2000). Insight and symptom change in schizophrenia and other disorders. Schizophr Res 45:29-36.
44. White L, Harvey PD, Opler L, Lindenmayer JP (1997). Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology30:263-274.